Fosun-Pharma-USA-Brand-2022

News & Media

FOSUN PHARMA USA INC

Fosun Pharma USA Announces Its Attendance at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco
Read More

December 11, 2023

Fosun Pharma USA Announces Abstract to be Presented at IASLC 2023 North America Conference on Lung Cancer (NACLC)
Read More

November 28, 2023

Fosun Pharma USA and Treehill Partners launch joint efforts for capital investments in biopharma space
Read More

November 20, 2023

FosunPharma and Henlius Partner
Fosun Pharma and Henlius Entered into an Exclusive License Agreement for Serplulimab in the US
Read More

January 7, 2023

SPSB Only FDA Approved 20ml Liquid
Fosun Pharma USA and MAIA Pharmaceuticals Jointly Announce the Successful Commercialization of Only FDA Approved 20ml Sodium Phenylacetate and Sodium Benzoate (SPSB) Liquid Product
Read More

September 26, 2022

Fosun Pharma and VerImmune enter into an Exclusive License and Option Agreement for VerImmune’s Virus-inspired Particle (ViP)…
Read More

May 23, 2022

Fosun Pharma 2021 Annual Results Announcement Accelerating the Globalization…
Read More

March 22, 2022

Fosun Pharma Signs Agreement with The Medicines Patent Pool (MPP)…
Read More

March 18, 2022

The NCCS and Fosun Pharma Partner to Help Patients In Guatemala
Read More

August 20, 2021

MEDIA ARCHIVE

104 Carnegie Center, Suite 204
Princeton, NJ 08540
(609) 250-2802

info.usa@fosunpharma.com
Customer Service & Adverse Event/ Quality Concerns: (855) 282-4882 or fosuncs@eversana.com

OUR WEBSITE

© 2024 Fosun Pharma USA Inc. All rights reserved.  |  Privacy Notice